PloS Biol (2020) 18(4):e3000704
2000 May;34(5):630-8
But this is only the beginning, with Ozempic and Wegovy both losing patent protection in China in 2026, in Europe and Japan in 2031, and in the US in 2032
By blocking Mcl-1, the peptide can force cancer cells to undergo programmed cell death
By targeting the SMAS layer beneath the dermis, Ultherapy tightly cinches the foundational tissue, causing the newly volumized, elastic skin to beautifully stick and adhere to the face, creating a seamless, sharp contour
Kennedy concludes, microdosing GLP-1s can be a practical, cost-effective alternative for patients who either cant tolerate full doses or are looking for a gentler on-ramp to treatment